Compass Pathways Surges as Depression Drug Trial Meets Key Milestones

Nearly 40% of participants receiving the treatment achieved a clinically meaningful response, according to data released by the biotechnology firm. The drug profile remains well-tolerated, providing a potential alternative to the frequent dosing schedules required by current standard-of-care medications.

Chief Executive Kabir Nath described the results as a catalyst for a broader shift in mental health treatment. The company is currently preparing a rolling new drug application for the U.S. Food and Drug Administration. If regulatory milestones are met, Compass aims to launch the therapy in the first half of next year.